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Estrogen Therapy and Coronary-Artery Calcification
Manson JE, Allison MA, Rossouw JE, et al; and the WHI-CACS Investiga-
tors. N Engl J Med 2007;356:2591-602.
Conclusion: Calcified plaque in coronary arteries of women is de-
creased by estrogen therapy compared with placebo.
Summary: Coronary artery calcified plaque is a marker of overall
atherosclerotic burden and is a predictor of future cardiovascular events. In
this study, the authors examined the relationship between coronary artery
calcification and estrogen therapy. This was a substudy of the Women’s
Health Initiative comparing conjugated equine estrogens (0.625 mg/d)
with placebo in women who had undergone hysterectomy.
Computed tomography (CT) of the heart was performed in 1064
women aged 50-59 years at the time of randomization in the Women’s
Health Initiative. Cardiac CT was performed after a mean of 7.4 years of
treatment. Coronary artery calcification was measured by Agatston scores.
Measurements were performed at a central reading center blinded to ran-
domization status.
Women receiving estrogens had lower mean coronary artery calcifi-
cation scores than those receiving placebo (83.1 vs 123.1, P  .02).
Adjusting for coronary risk factors, the odds ratios (95% confidence
intervals [CI]) for coronary artery calcium scores of 0, 10, and 100
in the group receiving estrogen compared with placebo were 0.78
(0.58-1.04), 0.74 (0.55-0.99), and 0.69 (0.48-0.98), respectively. In
women with at least 80% adherence to the study estrogen or placebo
dosages, the odds ratios were 0.64 (P  .01), 0.55 (P  .001), and 0.46
(P  .001). In an intention-to-treat analysis, the odds ratio for coronary
artery calcification scores of 300 vs 10 was 0.58 (P  .03). Among
women with at least 80% adherence, the odds ratio for coronary artery
calcification scores of 300 vs 10 was 0.39 (P  .004).
Comment: The data suggest estrogen therapy in middle-aged
women (therapy was initiated in women 50-59 years old) may result in
reduced plaque burden in the coronary arteries and, by inference, a
reduction in subclinical coronary artery disease and overall atheroscle-
rotic disease. The biologic effects of estrogen are complicated, and
estrogen replacement therapy may be associated with adverse venous
events. The overall benefit of estrogen replacement therapy for cardio-
vascular disease can only be established through large scale randomized
trials with clinical end points.
Oral Anticoagulant and Antiplatelet Therapy in Peripheral Arterial
Disease
The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. N Engl J
Med 2007;357:217-27.
Conclusion:The combination of an oral anticoagulant and antiplatelet
therapy is no more effective than antiplatelet therapy alone in preventing
major cardiovascular complications in patients with peripheral arterial dis-
ease (PAD). Combination therapy is associated with an increase in life-
threatening bleeding.
Summary: Antiplatelet drugs are known to reduce the risk of myocar-
dial infarction (MI), stroke, and death from cardiovascular causes in patients
with PAD. It is unknown if oral anticoagulant agents can provide added
benefit to antiplatelet drugs in reducing these complications. The authors
sought to compare patients with PAD treated with combination therapy vs
an antiplatelet agent alone. Those patients treated with combination therapy
had a target international normalized ratio of 2.0 to 3.0 for oral anticoagu-
lant therapy. One primary outcome was MI, stroke, or death from cardio-
vascular causes. The second primary outcome was MI, stroke, severe isch-
emia of the periphery or coronary arteries leading to an urgent intervention,
or death from cardiovascular causes.
This was a randomized, open-label, clinical trial at 80 centers from
Canada, Poland, Hungary, the Ukraine, China, the Netherlands, and Aus-
tralia. Patients were men and women aged 35 to 85 years with known PAD
defined as evidence of atherosclerosis of the lower extremities, carotid, or
subclavian arteries. Excluded patients had an indication for oral anticoagu-
lation therapy other than participation in this study, patients receiving
dialysis, those whowere actively bleeding or at high risk of bleeding, or those
who had had a stroke 6 months before enrollment.
A total of 2161 patients were enrolled and randomized. Mean fol-
low-up was 35 months. Stroke, MI, or death from a cardiovascular cause
occurred in 132 of 1080 patients receiving combination therapy and in 144
of 1081 patients receiving antiplatelet therapy (12.2% vs 13.3%; relative risk,
0.92; 95% confidence interval [CI], 0.73-1.16; P .48). MI, stroke, severe
ischemia requiring urgent intervention, or death from cardiovascular causes
occurred in 172 patients receiving combination therapy vs 188 patients
receiving antiplatelet therapy (15.9% vs 17.4%; relative risk, 0.91; 95% CI,
0.74-1.12, P  .37). There was a higher incidence of life-threatening
bleeding in the patients receiving combination therapy (4.0% vs 1.2%;
relative risk, 3.41; 95% CI, 1.84-6.35, P  .001).
Comment: The results are consistent with a previous study published
in Journal of Vascular Surgery detailing the results of Department of Veter-
an’s Affairs cooperative study (J Vasc Surg 2002;35:413-21). It is clearly not
indicated to add oral anticoagulation therapy to antiplatelet therapy in
patients with PAD where the sole indication is an attempt to reduce stroke,
MI, death from cardiovascular causes, or prevent acute ischemic events of
native arteries. Data do not apply to prevention of occlusion of vascular
grafts.
Consistent Platelet Inhibition During Long-TermMaintenance Clopi-
dogrel Therapy Among Three Hundred Fifty-Nine Compliant Outpa-
tients with Documented Vascular Disease
Serebruany VL, Malinin AI, Atar D, et al. Am Heart J 2007;153:371-7.
Conclusion: Long-term therapy with clopidogrel provides more con-
sistent platelet inhibition than that observed following initiation of therapy
after acute vascular events.
Summary: There have been conflicting reports on the effects of
clopidogrel therapy on platelet inhibition after an acute vascular event. Some
reports have documented a high incidence of clopidogrel nonresponsive-
ness, but these reports have been complicated by varying definitions and
different platelet aggregation tests. This study sought to assess the effect of
clopidogrel on platelet characteristics in outpatients who received mainte-
nance dosages of clopidogrel (75 mg/d) for30 days. This was a secondary
analysis of presumably compliant patients treated with clopidogrel and
aspirin. The patient cohort consisted of 237 who had undergone coronary
artery stenting and 122 who had sustained an ischemic stroke.
Themean duration of treatment was 5.8months (range, 1-21months).
All patients exhibited inhibition of adenosine diphosphate-induced platelet
activation (mean, 52.9%; range, 36%-70%) compared with preclopidogrel
measurements. A diminished expression of platelet-endothelial cell adhesion
molecule 1 (r  0.75), glycoprotein 2B-3A (r  0.62), and protease-
activated receptor 1 (r 0.71) were all correlated with inhibition of platelet
aggregation. No patients were found to have platelet hyporesponsiveness or
profound inhibition of platelet activity.
Comment: The wide response variability to clopidogrel in the acute
setting does not hold up with more long-term administration of the drug.
The article suggests that problems related to clopidogrel resistance may be
exaggerated by previous emphasis on short-term rather than long-term
maintenance data.
Anticoagulation for Three vs. Six Months in Patients With Deep Vein
Thrombosis or Pulmonary Embolism, or Both: Randomized Trial
Campbell IA, Bentley DP, Prescott RJ, et al. BMJ 2007;334:674-7.
Conclusion: There is little advantage in increasing the duration of
anticoagulation from 3 to 6 months in patients with deep vein thrombosis
(DVT) or pulmonary embolism (PE) and no known risk factors for recur-
rence.
Summary: This was a multicenter prospective randomized study with
1 year of follow-up. The objective was to determine the optimal duration of
anticoagulation therapy after an episode of DVT or PE. The study took place
in 46 hospitals in the United Kingdom and involved patients aged18 years
old randomized to either 3 or 6months of warfarin therapy beginning on the
first of 5 scheduled days of heparin administration after the diagnosis of
venous thromboembolism (VTE). The target international normalized ratio
was 2.0 to 3.5. There were 369 patients randomized to 3 months and 380
randomized to 6 months of oral anticoagulant therapy. Main outcomes
measures included death from VTE, failure to resolve, extension of clot,
recurrence of VTE during treatment, recurrence after treatment, and major
hemorrhage during treatment.
Two of the patients allocated to 3 months of treatment died from VTE
during or after treatment. Three patients allocated to 6 months of treatment
died secondary to VTE.During treatment in the 3-month group, VTE failed
to resolve, extended, or recurred in six patients. There were no fatal
consequences. In the 6-month group, VTE failed to resolve, extended, or
recurred in 10 patients, without fatal consequences.
After completion of treatment, there were 23 non-fatal recurrences of
VTE in the 3-month group and 16 non-fatal recurrences of VTE in the
1306
6-month group. Overall, fatal and nonfatal VTE during and after treatment
occurred in 8% of those receiving 3 months of anticoagulation (n 31) and
in 8% of those receiving 6 months anticoagulation (n  29; P  .80; 95%
confidence interval [CI] difference, –3.1% to 4.7%). No patients in either
group had a fatal hemorrhage during treatment, but there were eight major
hemorrhages in those treated for 6 months and none in those treated for 3
months (P .008; 95% CI, –3.5% to –0.7%). Adverse events occurred in 8%
of the patients receiving 3 months of anticoagulation (n 31) and in 9% of
the patients receiving 6 months of anticoagulation (n 35; P .79, 95% CI
–4.9% to 3.2%).
Comment: The data with regard to the hard end points in this
study—death from VTE or major hemorrhage—are likely reliable. The data
with respect to recurrence, extension, or failure to resolve VTE are likely
highly unreliable because they were derived from review forms completed by
clinicians at each individual site, without specific requirements for imaging
during follow-up. Indeed, the idea that the DVT resolved in 95% of the
patients treated with oral anticoagulation is completely disparate with regard
to the findings of serial imaging studies in patients with DVT. The authors
also provide no information about possible postphlebitic syndrome in their
patients. Follow-up is too short for such an analysis. Overall, the study
indicates no difference in death from VTE with 3 or 6 months of anticoag-
ulation in a patient with VTE and unidentified risk factors. The data are not
sufficient to conclude that there is no difference in recurrence of VTE with
the two treatment paradigms.
Heritability of Platelet Responsiveness to Aspirin in Activation Path-
ways Directly and Indirectly Related to Cyclooxygenase-1
Faraday N, Yanek LR, Mathias R, et al. Circulation 2007;115:2490-6.
Conclusion: There is a genetic basis to variability in residual platelet
function after aspirin exposure.
Summary: It is known that the inability of aspirin to suppress platelet
function can be associated with future risk of myocardial infarction, stroke,
and cardiovascular death. The authors sought to determine if there was
genetic variation that could be linked to insufficient aspirin responsiveness.
Aspirin responsiveness was assessed in 1880 asymptomatic patients.
The mean age was 44  13 years, and 58% were women. Patients were
recruited from 309 white and 208 black families with premature coronary
heart disease. Platelet function was determined ex vivo before and after
ingestion of aspirin (81mg/d for 2 weeks). Platelet function was determined
with a panel of tests assessing platelet activation in pathways indirectly and
directly related to cyclooxygenase-1 (COX-1). Multivariable regression
analysis was also used to determine the proportion of phenotypic variance
related to coronary heart disease risk factor covariates.
Arachidonic acid–induced thromboxane B2 production was inhibited
by99% with aspirin (P .0001). Platelet activation by pathways indirectly
related to COX-1 and inhibition of urinary thromboxane excretion was
more variable, with inhibition rates varying from 0% to 100%. Covariates
contributed somewhat to variability in aspirin responsiveness (r2  0.001-
0.133). Direct COX-1 phenotypes were not heritable across races. Pheno-
types indirectly related to COX-1 were consistently and strongly heritable
across races (r2  0.266-0.762; P  .01).
Comment: This is the first study to demonstrate that responsiveness to
aspirin is highly heritable. This applies particularly to phenotypic responses
in activation pathways that are indirectly related to COX-1. The study is also
the first to demonstrate that heritable factors contribute more strongly than
traditional cardiac risk factors to individual variability in residual platelet
function after aspirin exposure. It may be that inadequate response to aspirin
therapy runs in families.
Mid-term Survival After Abdominal Aortic Aneurysm Surgery Pre-
dicted by Cardiopulmonary Exercise Testing
Carlisle J, Swart M. Br J Surg 2007;94:966-9.
Conclusion:Cardiopulmonary exercise (CPX) testing, in combination
with comorbidity scoring, identifies patients unlikely to survive in the
mid-term after successful abdominal aortic aneurysm (AAA) repair.
Summary: The purpose of AAA repair is to prevent aneurysm-related
death. Patients at high risk of death from other causes are unlikely to benefit
overall from AAA repair. A number of risk factors found on history and
physical examinations correlate with survival after surgery. CPX testing
identifies patients at increase risk of dying after surgery (Chest 1999;116:
355-62). In this study the authors sought to determine whether preopera-
tive CPX testing could predict survival after elective open AAA repair.
Patients were also assessed with the Simplified Acute Physiology Score
(SAPS) II, the Acute Physiology and Chronic Health Evaluation
(APACHE) II score, and the Physiological and Operative Severity Score for
the enUmeration of Mortality and morbidity (POSSUM). CPX fitness was
determined with equipment measuring ventilatory minute volume, oxygen
consumption, and carbon dioxide while subjects pedaled an exercise bicycle.
Four variables were derived from CPX exercise measurements: anaerobic
threshold, peak oxygen consumption (V˙O2 peak), and ventilatory equiva-
lents for oxygen (V˙E/O2) and carbon dioxide (V˙E/V˙CO2). The Revised
Cardiac Risk Index (RCRI) was also determined for each patient, with one
point assigned for AAA repair, history of ischemic heart disease, history of
heart failure, cerebrovascular disease, insulin-dependent diabetes, and a
preoperative serum creatinine concentration of about 177 mol/L.
Multivariable analysis indicated that survival to 30 days and for the total
observation period correlated best with V˙E/V˙CO2. An increase in V˙E/
V˙CO2 by one unit increased the hazard ratio for death over the total
observation period by 1.13 for each unit increase. RCRI was also associated
with mid-term survival, as was anaerobic threshold.
Unfit patients were then defined as those with an RCRI 1 and a
V˙E/V˙CO2 of42, and fit patients were then defined as those with an RCRI
of 1 (and any V˙E/V˙CO2), or an RCRI 1 but V˙E/V˙CO2 43. This
definition provided 30 unfit patients and 100 fit patients for analysis. The 30
unfit patients were followed up for a total of 58 patient-years, and the 100 fit
patients for a total of 278 patient-years. Two-year survival for the fit patients
was 97%. Two-year survival for the unfit patients was 55% (95% confidence
interval, 18%-65%; P 178 .001).
Comment: A significant problem with this study is that the distinction
between fit and unfit patients was determined by observed mortality. Addi-
tional data based on prospective classification of patients undergoing open
AAA repair is required to assess whether the retrospective analysis used to
determine fit vs unfit potentially overestimated differences between groups.
Nevertheless, it is unlikely that even patients with relatively large AAAs
would experience a 55% rupture rate 2 years. The data suggest, as previ-
ously suggested by the Endovascular Aneurysm Repair II Trial (Lancet
2005;365:2187-92), that repair of AAAs in the marginally fit or unfit patient
may be more about surgical technical skill than overall patient benefit.
Impact of Endoluminal Treatment on Small Abdominal Aortic Aneu-
rysm: Aneurysm Sac Regression and Secondary Interventions With 5
Years of Follow-up
Hao Bui, Lujan R, Nguyen A, et al. Vasc Endovasc Surg 2007;41:294-300.
Conclusion: Endovascular intervention for small abdominal aortic
aneurysms (AAAs) does not result in faster aneurysm sac regression or lower
rates of secondary intervention.
Summary: It has been suggested endovascular repair be applied to
small AAAs in an attempt to reduce secondary intervention rates associated
with endovascular repair of larger AAAs. The authors reviewed 374 patients
who underwent endovascular AAA repair between 1996 and 2006. Of these
patients, 75 (20%) had a small AAA defined by an aneurysm sac diameter to
aortic diameter ratio of2 at the level of the renal arteries, and 299 patients
had larger AAAs.
There were no significant differences in operative times or operative
blood loss in patients undergoing endovascular repair for small AAAs vs
those undergoing repair of larger AAAs. In the patients treated for small
AAAs, 25.3% developed endoleaks compared with 36.1% of patients treated
for larger AAAs (P  .1). Over a mean follow-up of 42 months (range,
1-109 months), 11 patients (14.7%) with small AAAs had secondary inter-
ventions. Of the patients with larger AAAs, 58 (19.4%) had secondary
interventions (P .41). At 5 years, small AAAs had a 2.5% regression in the
aneurysm sac volume but a 3.0% increase in aneurysm diameter. Patients
with large AAAs had slight increases in sac diameter (3.3%) at 1 month but
steady decreases in sac volume (–13.4%) and aneurysm diameter (–8.8%)
over 5 years.
Comment: The data argue against early intervention with endovascu-
lar techniques for small AAAs. Previous data from the University of Texas
Southwestern Medical Center suggests waiting for small AAAs to enlarge to
5 to 5.5 cm does not reduce the applicability of endovascular techniques for
their repair. Given those data, the relatively benign natural history of small
AAAs, and the data presented here, it seems difficult to justify repair of small
AAAs with endovascular techniques outside the context of a clinical trial.
Renal Insufficiency Following Contrast Media Administration Trial
(REMEDIAL): A Randomized Comparison of 3 Preventive Strategies
Briguori C, Airoldi F, D’Andrea D, et al. Circulation 2007;115:1211-7.
Conclusion: A combination of volume supplementation by sodium
bicarbonate plus N-acetylcysteine (NAC) provides better renal protection
after contrast administration in patients with chronic kidney disease (CKD)
than strategies of hydration with a combination of normal saline andNAC or
the addition of ascorbic acid.
Summary:The optimal strategy for preventing contrast agent–induced
nephrotoxicity (CIN) in patients with CKD is uncertain. Guidelines suggest
volume expansion with saline, along with use of low or iso-osmolar contrast
agents and limits on the volume of contrast agent (Kidney Int 2006;69:S51-
3). Additional strategies focus on the use of antioxidants because reactive
oxygen species are considered an important pathophysiologic cause of CIN
(Kidney Int 2005;68:14-22). Both NAC and ascorbic acid have antioxidant
properties.
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